Stelara may join list of NICE psoriasis recommendations
This article was originally published in Scrip
Executive Summary
Health technology assessors for England and Wales have drafted guidance for the national health service that recommends Janssen-Cilag's (Johnson & Johnson) Stelara (ustekinumab) as a clinically and cost-effective treatment for psoriasis in limited circumstances.